Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results

REHOVOT, Israel and JERSEY CITY, New Jersey, August 12 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release first quarter financial results on August 19, 2008, before the U.S. markets open. Rosetta Genomics will host a conference call with a simultaneous webcast to discuss these results at 8:30 a.m. ET on Tuesday, August 19. To access the live conference call, U.S. and Canadian participants may dial 1-866-966-5335; international participants may dial +44-20-3023-4460. To access the 24-hour audio replay, U.S. and Canadian participants may dial 1-866-583-1035; international participants may dial 44-20-8196-1998. The access code for the replay is 181543#. The replay will be available until August 26, 2008.

REHOVOT, Israel and JERSEY CITY, New Jersey, August 12 /PRNewswire/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release first quarter financial results on August 19, 2008, before the U.S. markets open. Rosetta Genomics will host a conference call with a simultaneous webcast to discuss these results at 8:30 a.m. ET on Tuesday, August 19.

To access the live conference call, U.S. and Canadian participants may dial 1-866-966-5335; international participants may dial +44-20-3023-4460. To access the 24-hour audio replay, U.S. and Canadian participants may dial 1-866-583-1035; international participants may dial 44-20-8196-1998. The access code for the replay is 181543#. The replay will be available until August 26, 2008.

A live audio webcast of the call will also be available on the "Investors" section of the company's website, http://www.RosettaGenomics.com. An archived webcast will be available on the Company's website approximately two hours after the event, and will be archived for 30 days thereafter.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNAs. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first microRNA diagnostic test applying Rosetta Genomics' technology has been approved for clinical use by the State of New York, and the company expects it will be launched by licensed clinical laboratories in the United States in 2008.

Contact: Media & Investors Ron Kamienchick T: +1-(646)-509-1893 E: investors@rosettagenomics.com

Contact: Media & Investors, Ron Kamienchick, T: 1-(646)-509-1893, E: investors@rosettagenomics.com

Old NID
31443
Categories
Cancer Research
By Anna Ohlden in Newswire on .

Categories

Latest reads

Article teaser image

No, Trump’s Executive Orders Can’t Cancel Your Rights.

Donald Trump does not have the power to rescind either constitutional amendments or federal laws by mere executive order, no matter how strongly he might wish otherwise. No president of the United…
Article teaser image

The US Discourages Pregnant Women From Drinking Alcohol - Vegetarian Diets Are Worse

The Biden administration recently issued a new report showing causal links between alcohol and cancer, and it's about time. The link has been long-known, but alcohol carcinogenic properties have been…
Article teaser image

In British Iron Age Culture, Margaret Thatcher Was The Norm

In British Iron Age society, land was inherited through the female line and husbands moved to live with the wife’s community. Strong women like Margaret Thatcher resulted.That was inferred due to DNA…